{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=5", "query": { "intervention": "Placebo (treatment C)", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 988, "total_pages": 99, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T08:34:43.694Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01730053", "title": "Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2012-11-30", "completion_date": "2014-05-31", "has_results": true, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-10-11T08:34:43.694Z", "location_count": 54, "location_summary": "Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fair Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730053" }, { "nct_id": "NCT02830542", "title": "SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clostridium Difficile Infection" ], "interventions": [ { "name": "SER-262", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seres Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2016-08", "completion_date": "2018-08", "has_results": false, "last_update_posted_date": "2023-02-06", "last_synced_at": "2026-10-11T08:34:43.694Z", "location_count": 22, "location_summary": "Athens, Alabama • Fountain Valley, California • La Mesa, California + 19 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Fountain Valley", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02830542" }, { "nct_id": "NCT02106975", "title": "Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lung Injury", "Sepsis" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DRUG" }, { "name": "Placebo: 5% Dextrose in water", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2014-04", "completion_date": "2018-01-08", "has_results": true, "last_update_posted_date": "2019-10-15", "last_synced_at": "2026-10-11T08:34:43.694Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Lexington, Kentucky • Cleveland, Ohio + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Richmond", "state": "Virginia" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02106975" }, { "nct_id": "NCT00662519", "title": "Neulasta in Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "Neulasta (Pegylated)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mixed Meal Tolerance Test (MMTT)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Blood test", "type": "OTHER" }, { "name": "DNA Test", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "12 Years to 45 Years" }, "enrollment_count": 21, "start_date": "2008-04", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2015-04-09", "last_synced_at": "2026-10-11T08:34:43.694Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00662519" }, { "nct_id": "NCT02690064", "title": "Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Acute Antioxidant", "type": "DIETARY_SUPPLEMENT" }, { "name": "Chronic Antioxidant", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Augusta University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 13, "start_date": "2015-04", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-10-11T08:34:43.694Z", "location_count": 1, "location_summary": "Augusta, Georgia", "locations": [ { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02690064" }, { "nct_id": "NCT01356160", "title": "GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "ribavirin tablet", "type": "DRUG" }, { "name": "GS-9451 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 351, "start_date": "2011-07", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-10-11T08:34:43.694Z", "location_count": 21, "location_summary": "Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Coronado", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01356160" }, { "nct_id": "NCT04530123", "title": "Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Celiac Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "TAK-101", "type": "DRUG" }, { "name": "Gluten", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 102, "start_date": "2022-06-23", "completion_date": "2026-01-08", "has_results": true, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-11T08:34:43.694Z", "location_count": 26, "location_summary": "Scottsdale, Arizona • Escondido, California • Poway, California + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Poway", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04530123" }, { "nct_id": "NCT01366196", "title": "Pregabalin for the Treatment of Pain After Posterior Spinal Fusions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lumbar Spinal Fusions" ], "interventions": [ { "name": "Pregabalin 150 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hospital for Special Surgery, New York", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "21 Years to 80 Years" }, "enrollment_count": 86, "start_date": "2008-10", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2022-04-14", "last_synced_at": "2026-10-11T08:34:43.694Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01366196" }, { "nct_id": "NCT01193361", "title": "Ph IIA Study (SOC +/- NS5B)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus" ], "interventions": [ { "name": "BMS-791325", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peg-interferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 39, "start_date": "2010-10", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2015-10-09", "last_synced_at": "2026-10-11T08:34:43.694Z", "location_count": 10, "location_summary": "Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193361" }, { "nct_id": "NCT05560646", "title": "A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometriosis" ], "interventions": [ { "name": "OG-6219", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Organon and Co", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 354, "start_date": "2022-10-25", "completion_date": "2025-05-28", "has_results": true, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-11T08:34:43.694Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, Connecticut + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05560646" } ] }